N-(5-chloro-2-hydroxyphenyl)-2,2,2-trifluoroacetamide | 93416-35-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-chloro-2-hydroxyphenyl)-2,2,2-trifluoroacetamide
• 英文别名: N-(5-chloro-2-hydroxyphenyl)trifluoroacetamide；N-(2-Hydroxy-5-chlorophenyl)trifluoroacetamide
• CAS: 93416-35-4
• 化学式: C₈H₅ClF₃NO₂
• 分子量: 239.581
• InChiKey: RTEFETBTRIIUON-UHFFFAOYSA-N

物化性质

• 熔点：
  220-222 °C
• 沸点：
  306.7±42.0 °C(Predicted)
• 密度：
  1.604±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(5-chloro-2-hydroxyphenyl)-2,2,2-trifluoroacetamide 在 氨 作用下， 以 甲醇 、 苯 为溶剂， 反应 40.0h， 生成 7,16-bis(3-amino-5-chloro-2-hydroxybenzyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane
  参考文献：
  名称：

  Diaza-18-Crown-6 Ligands Containing Two Aminophenol Side Arms:  New Heterobinuclear Metal Ion Receptors

  摘要：

  Three diaza-18-crown-6 ligands substituted with two aminophenol side arms were synthesized as possible heterobinuclear metal ion receptors. Bis(p-aminophenol)-substituted diaza-18-crown-6 ligand (13) was prepared by treating the diazacrown with alpha-bromo-4-nitro-o-cresol in the presence of N,N-diisopropylethylamine followed by reduction of the nitro groups. Bis(o-aminophenol)substituted diaza-18-crown-6 ligands (11 and 12) were prepared in two steps by the aminomethylation of either an o-nitrophenol or o-(trifluoroacetamido)phenol followed by reduction of the nitro groups or hydrolysis of the trifluoroacetamide groups. All new bisphenol-armed diazacrown ligands were purified by ultrasonication in MeOH followed by filtration and drying. Interaction of the ligands with Na+, K+, Ag+, and Cu2+ was evaluated by a calorimetric titration technique at 25 degrees C in MeOH. The complexes of Ag+ and Cu2+ much more stable than those of Na+ and K+. Heterobinuclear complexes were observed for 11-Cu2+- Na+ and 12-Cu2+-Na+ but not for 13-Cu2+-Na+ or for 12-Cu2+-Ag+.

  DOI：

  10.1021/jo9816212
• 作为产物：
  描述：

  4-氯-2-氨基苯酚 在 吡啶 、 盐酸 、 三氟乙酸酐 作用下， 以 ice-water 、 乙醚 、 乙醇 为溶剂， 生成 N-(5-chloro-2-hydroxyphenyl)-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  3-(2-aminomethyl)-4-[3-trifluoromethyl)benzoyl]-3-4

  摘要：

  通式(I)的化合物##STR1##，其中R.sub.1代表氢、氟或氯原子或甲基、C.sub.1 -C.sub.3烷氧基或硝基；R.sub.3代表氢原子或C.sub.1 -C.sub.3烷基；R.sub.4代表2,3-二氢-1H-茚-2-基、2,3-二氢-1H-茚-1-基或1,2,3,4-四氢萘-1-基；或者R.sub.3和R.sub.4与它们连接的氮原子共同构成1,2,3,4-四氢-9H-吡啶并[3,4-b]吲哚-2-基、1,2,3,4-四氢-9H-吡啶并[4,3-b]吲哚-3-基、4,5,6,7-四氢噻吩并[2,3-c]吡啶-6-基、4,5,6,7-四氢噻吩并[3,2-c]吡啶-6-基或2,3-二氢-1H-异吲哚-2-基；对于治疗和预防脑部疾病很有用。

  公开号：

  US05550125A1

文献信息

• Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient
  申请人：——

  公开号：US20030060460A1

  公开（公告）日：2003-03-27

  The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: 1 (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z 1 is —COR 1 , —CH═CH—COR 1 etc.; Z 2 is H, alkyl etc.; Z 3 is single bond, alkylene; Z 4 is SO 2 , CO; Z 5 is alkyl, phenyl, heterocyclic ring etc.; R 2 is CONR 8 , O, S, NZ 6 , Z 7 -alkylene, alkylene etc.; R 3 is H, alkyl, halogen, CF 3 etc.; R 4 is H, (substituted) alkyl etc.; n, t is 1-4). The compounds of the formula (I) can bind to receptors of PGE 2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.

  公式（I）的磺酰胺或羧酰胺衍生物以及包含它们作为活性成分的制药组合物： 1（其中A环，B环为碳环，杂环；Z1为—COR1，—CH═CH—COR1等；Z2为H，烷基等；Z3为单键，烷基；Z4为SO2，CO；Z5为烷基，苯基，杂环等；R2为CONR8，O，S，NZ6，Z7-烷基，烷基等；R3为H，烷基，卤素，CF3等；R4为H，（取代）烷基等；n，t为1-4）。 公式（I）的化合物可以与PGE2受体结合，并显示其作用的拮抗活性或激动活性。因此，它们被认为是用于抑制子宫收缩、镇痛药、止泻药、催眠剂、增加膀胱容量的药物或子宫收缩药物、泻药、抑制胃酸分泌、降压或利尿剂的有用药物。
• Dérivés de 3-(2-aminoéthyl)-4-(3-(trifluorométhyl)benzoyl)-3,4-dihydro-2H-1,4-benzoxazine, leur préparation et leur application en thérapeutique
  申请人：SYNTHELABO

  公开号：EP0666260A1

  公开（公告）日：1995-08-09

  Composés répondant à la formule générale (I) dans laquelle R₁ représente un atome d'hydrogène, de fluor ou de chlore ou un groupe méthyle, alcoxy en C₁-C₃ ou nitro, R₃ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₃, R₄ représente un groupe 2,3-dihydro-1H-indén-2-yle, 2,3-dihydro-1H-indén-1-yle ou 1,2,3,4-tétrahydronaphtalén-1-yle, ou bien R₃ et R₄ forment, avec l'atome d'azote, un groupe 1,2,3,4-tétrahydro-9H-pyrido[3,4-b]indol-2-yle, 1,2,3,4-tétrahydro-9H-pyrido[4,3-b]indol-3-yle, 4,5,6,7-tétrahydrothiéno[2,3-c]pyridin-6-yle, 4,5,6,7-tétrahydrothiéno[3,2-c]pyridin-6-yle ou 2,3-dihydro-1H-isoindol-2-yle.

  通式(I)对应的化合物 其中 R₁ 代表氢原子、氟原子或氯原子或甲基、C₁-C₃ 烷氧基或硝基，R₃ 代表氢原子或 C₁-C₃ 烷基，R₄ 代表 2,3-二氢-1H-茚-2-基、2,3-二氢-1H-茚-1-基或 1,2,3、4-四氢萘-1-基，或 R₃ 和 R₄ 与氮原子一起形成 1,2,3,4-四氢-9H-吡啶并[3,4-b]吲哚-2-基、1,2,3、4-tétrahydro-9H-pyrido[4,3-b]indol-3-yle, 4,5,6,7-tétrahydrothiéno[2,3-c]pyridin-6-yle, 4,5,6,7-tétrahydrothiéno[3,2-c]pyridin-6-yle ou 2,3-dihydro-1H-isoindol-2-yle.
• SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0947500A1

  公开（公告）日：1999-10-06

  The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is -COR1, -CH=CH-COR1 etc.; Z2 is H, alkyl etc.; Z3 is single bond, alkylene; Z4 is SO2, CO; Z5 is alkyl, phenyl, heterocyclic ring etc.; R2 is CONR8, O, S, NZ6, Z7-alkylene, alkylene etc.; R3 is H, alkyl, halogen, CF3 etc.; R4 is H, (substituted) alkyl etc.; n, t is 1-4). The compounds of the formula (I) can bind to receptors of PGE2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.

  式(I)的磺酰胺或羧酰胺衍生物以及包含它们作为活性成分的药物组合物： (其中 A 环、B 环为碳环、杂环；Z1 为-COR1、-CH=CH-COR1 等；Z2 为 H、烷基等；Z3 为单键、亚烷基；Z4 为 SO2、CO；Z5 为烷基、苯基、杂环等。R2 是 CONR8、O、S、NZ6、Z7-烷基、亚烷基等；R3 是 H、烷基、卤素、CF3 等；R4 是 H、（取代的）烷基等；n、t 是 1-4）。 式（I）化合物可与 PGE2 受体结合，并显示出对其作用的拮抗活性或激动活性。因此，它们被认为可用作抑制子宫收缩的药物、镇痛药、止泻药、睡眠诱导剂、增加膀胱容量的药物或子宫收缩的药物、泻药、抑制胃酸分泌的药物、降压药或利尿剂。
• Synthese de F-alkyl-2 benzoxazoles
  作者：J. Greiner、R. Pastor、A. Cambon

  DOI：10.1016/s0022-1139(00)81483-9

  日期：1984.8
• Metal-Free Chemoselective ortho-C(sp2)–F Bond Hydroxylation and N-Trifluoroacylation of Fluoroarylamines for Domino Synthesis of 2-(N-Trifluoroacyl)aminophenols
  作者：Sanghapal Sawant、Vunnam Venkateswarlu、Shilpi Balgotra、K. Aravinda Kumar、Ram Vishwakarma

  DOI：10.1055/s-0034-1379905

  日期：——

  A novel chemoselective reaction for the formation of C-O bonds by C(sp(2))-F bond cleavage and concomitant N-trifluoroacylation of fluoroanilines using trifluoroacetic acid and Oxone((R)) is presented. This domino reaction gives o-hydroxy-N-trifluoroacetanilides in good yields under metal-free conditions in a single step. Selective ortho-directed monohydroxylation and N-trifluoroacylation of 2- and 6-fluoro- or 2,6-difluoro-substituted anilines takes place in this transformation.